News for BiondVax Pharmaceuticals Ltd. (BVXV)

PR NewswireJERUSALEM, Nov. 22, 2024 JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a

JERUSALEM, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company formerly known as...

Scinai Immunotherapeutics to debut tomorrow under Nasdaq ticker symbol “SCNI” ...

/PRNewswire/ -- The "Global Influenza Vaccines Market, Persons Vaccinated, Key Company Analysis, Emerging Players Profile, Promising Influenza Vaccines in...

JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing,...

Nasal vaccines have emerged as a significant advancement in the field of vaccination, providing enhanced protection for both the vaccinated individuals and...

SkyQuest projects that the influenza vaccine market will attain a USD 12.37 billion value by 2030, with a CAGR of 6.83% over the forecast period...

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on August 24, 2023 The Annual General Meeting of Shareholders of BiondVax Pharmaceuticals Ltd. will...

Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive...

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on...

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 400 points on Friday.

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 200 points on Friday.

/PRNewswire/ --The influenza vaccine market is set to grow by USD 2.56 billion, at a CAGR of 8.66% from 2021 to 2026. The report offers an up-to-date analysis...

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession...